ホーム
おまかせ表示
ログイン
設定
脳科学辞典について
免責事項
脳科学辞典
検索
Nafoxidineのソースを表示
←
Nafoxidine
あなたには「このページの編集」を行う権限がありません。理由は以下の通りです:
この操作は、次のグループに属する利用者のみが実行できます:
登録利用者
。
このページのソースの閲覧やコピーができます。
{{short description|Chemical compound}} {{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = 1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine | image = Nafoxidine.svg | width = 200px <!--Clinical data--> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category = | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = [[Oral administration|By mouth]] <!--Pharmacokinetic data--> | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = <!-- Identifiers --> | CAS_number_Ref = | CAS_number = 1845-11-0 | CAS_supplemental = | class = | ATC_prefix = None | ATC_suffix = | ATC_supplemental = | PubChem = 4416 | IUPHAR_ligand = 4263 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 4263 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 4RIY10WM82 | KEGG = C14212 | ChEBI = 34881 | ChEMBL = 28211 | synonyms = U-11,000A; NSC-70735 <!--Chemical data--> | C=29 | H=31 | N=1 | O=2 | SMILES = COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCCN5CCCC5 | StdInChI_Ref = | StdInChI = 1S/C29H31NO2/c1-31-26-14-16-28-24(21-26)11-15-27(22-7-3-2-4-8-22)29(28)23-9-12-25(13-10-23)32-20-19-30-17-5-6-18-30/h2-4,7-10,12-14,16,21H,5-6,11,15,17-20H2,1H3 | StdInChIKey_Ref = | StdInChIKey = JEYWNNAZDLFBFF-UHFFFAOYSA-N }} '''Nafoxidine''' ({{Abbrlink|INN|International Nonproprietary Name}}; developmental code names '''U-11,000A''') or '''nafoxidine hydrochloride''' ({{Abbrlink|USAN|United States Adopted Name}}) is a [[nonsteroid]]al [[selective estrogen receptor modulator]] (SERM) or [[partial agonist|partial]] [[antiestrogen]] of the [[triphenylethylene]] group that was developed for the treatment of [[metastatic cancer|advanced]] [[breast cancer]] by [[Upjohn]] in the 1970s but was never marketed.<ref name="Elks2014">{{Cite book |url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA848 |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies |vauthors=Elks J |date=14 November 2014 |publisher=Springer |isbn=978-1-4757-2085-3 |pages=848–}}</ref><ref name="CRAIGFurr2010">{{Cite book |url=https://books.google.com/books?id=dM0uvBnxiN0C&pg=PA95 |title=Hormone Therapy in Breast and Prostate Cancer |vauthors=Craig JV, Furr BJ |date=5 February 2010 |publisher=Springer Science & Business Media |isbn=978-1-59259-152-7 |pages=95–96}}</ref><ref name="Weber2015">{{Cite book |url=https://books.google.com/books?id=dhs_CgAAQBAJ&pg=PA361 |title=Molecular Therapies of Cancer |vauthors=Weber GF |date=22 July 2015 |publisher=Springer |isbn=978-3-319-13278-5 |pages=361–}}</ref> It was developed at around the same time as [[tamoxifen]] and [[clomifene]], which are also triphenylethylene derivatives.<ref name="CRAIGFurr2010" /> The drug was originally synthesized by the fertility control program at Upjohn as a [[emergency contraception|postcoital contraceptive]], but was subsequently repurposed for the treatment of breast cancer.<ref name="Elsevier2013">{{Cite journal |vauthors=McDaniel RE, Maximov PY, Jordan VC |date=2013 |title=Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story |url=https://books.google.com/books?id=vBvzF6HQ4-QC&pg=PA32 |journal=Vitamins and Hormones |volume=93 |pages=1–49 |doi=10.1016/B978-0-12-416673-8.00007-1 |pmid=23810002}}</ref> Nafoxidine was assessed in clinical trials in the treatment of breast cancer and was found to be effective.<ref name="pmid27889048">{{Cite journal |vauthors=Coelingh Bennink HJ, Verhoeven C, Dutman AE, Thijssen J |date=January 2017 |title=The use of high-dose estrogens for the treatment of breast cancer |journal=Maturitas |volume=95 |pages=11–23 |doi=10.1016/j.maturitas.2016.10.010 |pmid=27889048 |doi-access=free}}</ref><ref name="Steinbaumde Jager1978">{{Cite journal |vauthors=Steinbaum FL, De Jager RL, Krakoff IH |year=1978 |title=Clinical trial of nafoxidine in advanced breast cancer |journal=Medical and Pediatric Oncology |volume=4 |issue=2 |pages=123–126 |doi=10.1002/mpo.2950040207 |pmid=661750}}</ref> However, it produced [[side effect]]s including [[ichthyosis]], partial [[alopecia|hair loss]], and [[phototoxicity]] of the skin in almost all patients,<ref name="pmid27889048" /> and this resulted in the discontinuation of its development.<ref name="Elsevier2013" /><ref name="Lupulescu1990">{{Cite book |url=https://books.google.com/books?id=VddUa-2cp-YC&pg=PA95 |title=Hormones and Vitamins in Cancer Treatment |vauthors=Lupulescu A |date=24 October 1990 |publisher=CRC Press |isbn=978-0-8493-5973-6 |pages=95–}}</ref> Nafoxidine is a long-acting [[estrogen receptor]] [[ligand (biochemistry)|ligand]], with a [[nuclear retention]] in the range of 24 to 48 hours or more.<ref name="WallachHammond1982">{{Cite journal |vauthors=Hammond CB, Maxson WS |date=January 1982 |title=Current status of estrogen therapy for the menopause |journal=Fertility and Sterility |volume=37 |issue=1 |pages=5–25 |doi=10.1016/S0015-0282(16)45970-4 |pmid=6277697}}</ref> {{Comparison of early clinical experience with antiestrogens for advanced breast cancer}} == References == {{Reflist}} {{Estrogen receptor modulators}} [[Category:Abandoned drugs]] [[Category:Hormonal antineoplastic drugs]] [[Category:Phenol ethers]] [[Category:1-Pyrrolidinyl compounds]] [[Category:Selective estrogen receptor modulators]] [[Category:Triphenylethylenes]]
Nafoxidine
に戻る。